SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

SOSA LIPRANDI, Alvaro et al. Rol del bloqueo aldosterónico en la insuficiencia cardíaca crónica. Insuf. card. [online]. 2012, vol.7, n.3, pp. 117-122. ISSN 1852-3862.

    1. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-545. [ Links ]

    2. Struthers AD, Unger T. Physiology of aldosterone and pharmacology of aldosterone blockers. Eur Heart J Suppl B 2011; 13: 27B-30B. [ Links ]

    3. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theise K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522. [ Links ]

    4. Struders A, Krum H, Williams GH. A comparison of aldosteroneblocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153-158. [ Links ]

    5. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. Isolation from the adrenals of a new crystalline hormone with specially high effectiveness on mineral metabolism. Experientia 1953; 9: 333-335. [ Links ]

    6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364. [ Links ]

    7. McFayden RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34. [ Links ]

    8. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000; 102: 2700-2706. [ Links ]

    9. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992; 19: 270-277. [ Links ]

    10. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001; 37: 1800-1807. [ Links ]

    11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al for the Randomized Aldactone Evaluation Study Investigator. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717. [ Links ]

    12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Investigators(EPHESUS) Eplerenona, a selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348:1309-1321. [ Links ]

    13. Zannad F, Alla F, Dousset D, Perez A, Pitt B, on behalf of the RALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102: 2700-2706. [ Links ]

    14. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fuji M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565. [ Links ]

    15. Sosa Liprandi A, Sosa Liprandi MI, Huerín M, Martínez F et al. Rol del bloqueo aldosterónico en la insuficiencia cardíaca post infarto agudo de miocardio. Insuf Card 2012; 7 (2): 61-66. [ Links ]

    16. Hunt SA et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2001 and ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation 2005; 112:e154-e235. [ Links ]

    17. Swedberg K, Cleland J, Dargie H et al. Guías de Práctica Clínica sobre diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida. Rev Esp Cardiol 2005; 58(9):1062-1092. [ Links ]

    18. Barisani JL et al. Consenso de diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Sociedad Argentina de Cardiología. Rev Argent Cardiol 2010; 78(2): 166-181. [ Links ]

    19. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-477. [ Links ]

    20. Zannad F, McMurray JV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364:11-21. [ Links ]

    21. Wel L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340: c1768. [ Links ]